(Q27612411)

English

CIViC database

an open access, open source, community-driven web resource for Clinical Interpretation of Variants in Cancer

CIVICdb
Clinical Interpretation of Variants in Cancer

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

0 references

0 references

0 references

0 references

Washington University School of Medicine

0 references

official website

https://civic.genome.wustl.edu/#/home

0 references

copyright license

Creative Commons CC0 License

0 references

copyright status

public domain

0 references

cites work

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

0 references

Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors

0 references

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

0 references

AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients

0 references

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

0 references

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome

0 references

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

0 references

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

0 references

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

0 references

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

0 references

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

0 references

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

0 references

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

0 references

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

0 references

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

0 references

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma

0 references

BRAF mutations in hairy-cell leukemia

0 references

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

0 references

Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration

0 references

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

0 references

Genome sequencing identifies a basis for everolimus sensitivity

0 references

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

0 references

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

0 references

The PI3K pathway as drug target in human cancer

0 references

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

0 references

IDH1 and IDH2 mutations in gliomas

0 references

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

0 references

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

0 references

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

0 references

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

0 references

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

0 references

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

0 references

DNMT3A Mutations in Acute Myeloid Leukemia

0 references

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

0 references

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

0 references

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

0 references

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

0 references

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

0 references

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

0 references

MEK1 mutations confer resistance to MEK and B-RAF inhibition

0 references

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

0 references

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

0 references

Cyclin E in human cancers.

0 references

A novel fusion gene, SYT-SSX4, in synovial sarcoma.

0 references

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors

0 references

Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis

0 references

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

0 references

Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics?

0 references

Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study

0 references

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy

0 references

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

0 references

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

0 references

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck

0 references

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

0 references

TP53 polymorphism, HPV infection, and risk of cervical cancer.

0 references

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

0 references

Fusions of the SYT and SSX genes in synovial sarcoma

0 references

All trans retinoic acid in acute promyelocytic leukemia

0 references

The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma

0 references

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

0 references

Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis

0 references

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

0 references

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

0 references

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

0 references

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

0 references

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

0 references

Cyclin E and survival in patients with breast cancer

0 references

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.

0 references

Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma

0 references

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

0 references

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol

0 references

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

0 references

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

0 references

The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.

0 references

TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis

0 references

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

0 references

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

0 references

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme

0 references

Promoter methylation of cyclin D2 gene in gastric carcinoma

0 references

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

0 references

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

0 references

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

0 references

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

0 references

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

0 references

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial

0 references

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

0 references

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

0 references

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

0 references

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential

0 references

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

0 references

Thymic carcinoma with overexpression of mutated KIT and the response to imatinib

0 references

Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance

0 references

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

0 references

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

0 references

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

0 references

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

0 references

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

0 references

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

0 references

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

0 references

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

0 references

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

0 references

MGMT gene silencing and benefit from temozolomide in glioblastoma

0 references

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line

0 references

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

0 references

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

0 references

Mutation and methylation analysis of TP53 in adrenal carcinogenesis.

0 references

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

0 references

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

0 references

Cyclin D1 in breast cancer pathogenesis

0 references

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

0 references

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

0 references

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

0 references

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

0 references

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

0 references

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor

0 references

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

0 references

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

0 references

The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians

0 references

Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma

0 references

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

0 references

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

0 references

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

0 references

Implications of NRAS mutations in AML: a study of 2502 patients

0 references

Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma

0 references

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

0 references

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy

0 references

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.

0 references

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

0 references

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

0 references

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

0 references

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

0 references

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

0 references

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

0 references

Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer

0 references

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

0 references

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

0 references

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

0 references

XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer

0 references

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

0 references

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

0 references

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders

0 references

Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation

0 references

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells

0 references

Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas

0 references

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

0 references

Clinical significance of TP53 mutation in myeloma

0 references

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

0 references

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

0 references

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

0 references

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

0 references

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer

0 references

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

0 references

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

0 references

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

0 references

Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium

0 references

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

0 references

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

0 references

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

0 references

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

0 references

Cetuximab for the treatment of colorectal cancer.

0 references

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

0 references

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

0 references

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

0 references

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

0 references

Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling

0 references

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

0 references

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

0 references

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

0 references

Major response to imatinib mesylate in KIT-mutated melanoma.

0 references

MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer

0 references

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

0 references

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

0 references

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

0 references

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

0 references

Clinical and biological significance of RAS mutations in multiple myeloma.

0 references

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

0 references

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

0 references

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

0 references

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

0 references

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer

0 references

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

0 references

Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

0 references

Penetrance analysis of the PALB2 c.1592delT founder mutation

0 references

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

0 references

The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.

0 references

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

0 references

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

0 references

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

0 references

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

0 references

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

0 references

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

0 references

Activating mutations in ALK provide a therapeutic target in neuroblastoma

0 references

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

0 references

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

0 references

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

0 references

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

0 references

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

0 references

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma

0 references

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

0 references

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

0 references

Aurora kinases as prognostic biomarkers in ovarian carcinoma.

0 references

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

0 references

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

0 references

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

0 references

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

0 references

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

0 references

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

0 references

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro

0 references

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

0 references

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics

0 references

ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes

0 references

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association

0 references

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

0 references

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer

0 references

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

0 references

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis

0 references

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

0 references

A novel K-ras mutation in colorectal cancer. A case report and literature review

0 references

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

0 references

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

0 references

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

0 references

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

0 references

KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors

0 references

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

0 references

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

0 references

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

0 references

Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.

0 references

Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.

0 references

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

0 references

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer

0 references

EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma

0 references

SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma

0 references

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

0 references

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy

0 references

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones

0 references

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

0 references

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

0 references

Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

0 references

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

0 references

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

0 references

p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus

0 references

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

0 references

Alterations of the Notch pathway in lung cancer.

0 references

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

0 references

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

0 references

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment

0 references

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

0 references

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

0 references

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

0 references

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

0 references

Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer

0 references

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

0 references

HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers

0 references

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

0 references

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

0 references

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study

0 references

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

0 references

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

0 references

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

0 references

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

0 references

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

0 references

Human papillomavirus and survival of patients with oropharyngeal cancer.

0 references

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review

0 references

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

0 references

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population

0 references

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

0 references

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

0 references

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

0 references

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

0 references

CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.

0 references

The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary

0 references

TP53 mutation and survival in chronic lymphocytic leukemia

0 references

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

0 references

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

0 references

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

0 references

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

0 references

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

0 references

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

0 references

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

0 references

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

0 references

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

0 references

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

0 references

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

0 references

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

0 references

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

0 references

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

0 references

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

0 references

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

0 references

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma

0 references

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

0 references

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer

0 references

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

0 references

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

0 references

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

0 references

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models

0 references

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

0 references

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study

0 references

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group

0 references

Crizotinib in anaplastic large-cell lymphoma

0 references

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

0 references

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

0 references

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

0 references

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial

0 references

Anti-tumor activity of motesanib in a medullary thyroid cancer model

0 references

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

0 references

DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer

0 references

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients

0 references

Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma

0 references

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

0 references

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas

0 references

Use of whole-genome sequencing to diagnose a cryptic fusion oncogene

0 references

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

0 references

The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations

0 references

NRAS-mutant melanoma: response to chemotherapy.

0 references

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer

0 references

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

0 references

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

0 references

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

0 references

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer

0 references

Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment

0 references

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

0 references

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

0 references

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

0 references

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

0 references

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target

0 references

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia

0 references

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

0 references

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

0 references

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers

0 references

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations

0 references

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

0 references

ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells

0 references

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers

0 references

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer

0 references

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients

0 references

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

0 references

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

0 references

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin

0 references

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

0 references

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

0 references

IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome

0 references

Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma

0 references

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

0 references

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

0 references

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients

0 references

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen

0 references

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

0 references

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

0 references

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

0 references

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

0 references

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

0 references

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study

0 references

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

0 references

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer

0 references

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

0 references

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

0 references

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

0 references

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

0 references

NRAS mutation status is an independent prognostic factor in metastatic melanoma

0 references

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

0 references

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

0 references

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

0 references

Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

0 references

ROS1 rearrangements define a unique molecular class of lung cancers

0 references

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

0 references

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

0 references

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

0 references

Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.

0 references

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

0 references

Sunitinib therapy for melanoma patients with KIT mutations

0 references

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors

0 references

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

0 references

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

0 references

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

0 references

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

0 references

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

0 references

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer

0 references

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background

0 references

Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer

0 references

The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells

0 references

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

0 references

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

0 references

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules

0 references

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

0 references

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

0 references

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

0 references

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

0 references

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

0 references

Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer

0 references

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

0 references

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

0 references

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group

0 references

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial

0 references

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

0 references

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

0 references

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

0 references

Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.

0 references

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

0 references

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

0 references

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

0 references

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer

0 references

High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy

0 references

Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model

0 references

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

0 references

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

0 references

Somatic STAT3 mutations in large granular lymphocytic leukemia

0 references

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

0 references

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

0 references

Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis

0 references

Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer

0 references

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy

0 references

The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort

0 references

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas

0 references

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

0 references

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia

0 references

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors

0 references

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures

0 references

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

0 references

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

0 references

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

0 references

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

0 references

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

0 references

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

0 references

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin

0 references

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

0 references

ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy

0 references

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

0 references

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

0 references

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

0 references

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

0 references

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

0 references

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

0 references

Trastuzumab emtansine for HER2-positive advanced breast cancer

0 references

U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome

0 references

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

0 references

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines

0 references

Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer

0 references

Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

0 references

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

0 references

CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients

0 references

Elucidating distinct roles for NF1 in melanomagenesis

0 references

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene

0 references

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

0 references

Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells

0 references

Ponatinib in refractory Philadelphia chromosome-positive leukemias

0 references

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

0 references

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

0 references

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

0 references

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer

0 references

Activating HER2 mutations in HER2 gene amplification negative breast cancer

0 references

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

0 references

A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal

0 references

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

0 references

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies

0 references

Biomarkers for the clinical management of breast cancer: international perspective

0 references

Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models

0 references

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

0 references

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

0 references

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer

0 references

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

0 references

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.

0 references

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

0 references

Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells

0 references

The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.

0 references

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

0 references

Advanced ovarian cancer: what should be the standard of care?

0 references

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

0 references

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

0 references

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

0 references

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

0 references

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer

0 references

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

0 references

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

0 references

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

0 references

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer

0 references

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

0 references

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

0 references

The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.

0 references

The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.

0 references

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

0 references

Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact

0 references

Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis

0 references

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

0 references

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.

0 references

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer

0 references

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

0 references

Identification of targetable FGFR gene fusions in diverse cancers.

0 references

Somatic mutations in exocrine pancreatic tumors: association with patient survival

0 references

SF3B1 mutations in chronic lymphocytic leukemia

0 references

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

0 references

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer

0 references

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.

0 references

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

0 references

A patient with lung adenocarcinoma and RET fusion treated with vandetanib

0 references

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

0 references

Targeting the BRAF V600E mutation in multiple myeloma

0 references

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

0 references

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

0 references

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

0 references

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

0 references

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

0 references

Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma

0 references

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML

0 references

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer

0 references

Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia

0 references

Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience

0 references

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma

0 references

Nivolumab plus ipilimumab in advanced melanoma

0 references

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

0 references

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

0 references

Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors

0 references

Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer

0 references

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

0 references

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

0 references

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

0 references

Comprehensive molecular characterization of clear cell renal cell carcinoma

0 references

Integrated molecular analysis of clear-cell renal cell carcinoma

0 references

Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma

0 references

Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer

0 references

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth

0 references

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

0 references

KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials

0 references

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

0 references

A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.

0 references

Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.

0 references

NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

0 references

Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells

0 references

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

0 references

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

0 references

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

0 references

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

0 references

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity

0 references

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

0 references

TERT promoter mutations in primary and secondary glioblastomas.

0 references

Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.

0 references

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

0 references

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation

0 references

The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma

0 references

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer

0 references

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

0 references

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

0 references

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma

0 references

Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors

0 references

Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer

0 references

A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report

0 references

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

0 references

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

0 references

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

0 references

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

0 references

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

0 references

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

0 references

RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib

0 references

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

0 references

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study

0 references

p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas

0 references

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

0 references

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

0 references

Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer

0 references

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

0 references

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

0 references

SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.

0 references

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma

0 references

Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response

0 references

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

0 references

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

0 references

Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation

0 references

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.

0 references

RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial

0 references

Therapeutic targeting of cancers with loss of PTEN function

0 references

Prognostic value of BRAF mutations in localized cutaneous melanoma.

0 references

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma

0 references

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

0 references

Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.

0 references

Oncogenic RIT1 mutations in lung adenocarcinoma

0 references

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

0 references

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

0 references

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

0 references

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

0 references

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.

0 references

DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.

0 references

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma

0 references

Regorafenib in metastatic colorectal cancer.

0 references

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

0 references

Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.

0 references

RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures

0 references

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

0 references

Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy

0 references

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

0 references

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma

0 references

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma

0 references

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

0 references

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors

0 references

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer

0 references

BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis

0 references

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

0 references

The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis

0 references

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

0 references

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.

0 references

Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.

0 references

Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition

0 references

EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis

0 references

Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.

0 references

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

0 references

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer

0 references

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis

0 references

Ceritinib in ALK-rearranged non-small-cell lung cancer

0 references

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

0 references

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

0 references

P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer

0 references

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients

0 references

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

0 references

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

0 references

Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis

0 references

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

0 references

Predictive value of CHFR and MLH1 methylation in human gastric cancer

0 references

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

0 references

A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service

0 references

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

0 references

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients

0 references

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials

0 references

Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.

0 references

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

0 references

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

0 references

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines

0 references

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

0 references

TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations

0 references

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study

0 references

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

0 references

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

0 references

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

0 references

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

0 references

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

0 references

Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells

0 references

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

0 references

Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro

0 references

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

0 references

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy

0 references

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

0 references

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

0 references

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

0 references

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial

0 references

Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.

0 references

Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma

0 references

Q27853031

0 references

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

0 references

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831

0 references

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

0 references

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines

0 references

Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group

0 references

Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response

0 references

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence

0 references

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

0 references

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF

0 references

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

0 references

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis

0 references

FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.

0 references

Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan

0 references

Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.

0 references

Prognostic parameters in uveal melanoma and their association with BAP1 expression

0 references

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

0 references

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

0 references

Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis

0 references

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

0 references

The genomic landscape of pediatric Ewing sarcoma

0 references

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

0 references

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib

0 references

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

0 references

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

0 references

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma

0 references

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

0 references

TERT gene amplification is associated with poor outcome in acral lentiginous melanoma

0 references

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

0 references

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

0 references

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

0 references

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

0 references

p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma

0 references

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

0 references

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

0 references

Response and acquired resistance to everolimus in anaplastic thyroid cancer

0 references

PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.

0 references

Mutational landscape of aggressive cutaneous squamous cell carcinoma

0 references

ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia

0 references

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

0 references

Resistant mutations in CML and Ph(+)ALL - role of ponatinib.

0 references

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

0 references

Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer

0 references

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

0 references

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib

0 references

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

0 references

Improved overall survival in melanoma with combined dabrafenib and trametinib

0 references

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib

0 references

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

0 references

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

0 references

Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival

0 references

SF3B1 mutations constitute a novel therapeutic target in breast cancer

0 references

FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis

0 references

Breast cancer in a RAD51D mutation carrier: case report and review of the literature

0 references

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

0 references

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

0 references

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.

0 references

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

0 references

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

0 references

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

0 references

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

0 references

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer

0 references

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel

0 references

Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models

0 references

Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs

0 references

In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer

0 references

Unique genomic profile of fibrolamellar hepatocellular carcinoma

0 references

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

0 references

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

0 references

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy

0 references

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

0 references

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

0 references

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

0 references

Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer

0 references

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

0 references

MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

0 references

EGFR T790M resistance mutation in non small-cell lung carcinoma

0 references

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer

0 references

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

0 references

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

0 references

Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.

0 references

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer

0 references

Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.

0 references

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

0 references

DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

0 references

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

0 references

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

0 references

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

0 references

Smoothened variants explain the majority of drug resistance in basal cell carcinoma

0 references

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

0 references

Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer

0 references

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

0 references

Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.

0 references

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.

0 references

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

0 references

Ibrutinib in previously treated Waldenström's macroglobulinemia.

0 references

Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies

0 references

Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion

0 references

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

0 references

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

0 references

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

0 references

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

0 references

TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer

0 references

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide

0 references

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

0 references

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

0 references

Rociletinib in EGFR-mutated non-small-cell lung cancer

0 references

Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma

0 references

Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4.

0 references

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

0 references

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma

0 references

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine

0 references

Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors

0 references

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

0 references

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

0 references

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients

0 references

Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer

0 references

Integrative clinical genomics of advanced prostate cancer

0 references

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers

0 references

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

0 references

Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma

0 references

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients

0 references

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

0 references

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

0 references

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

0 references

Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review

0 references

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

0 references

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

0 references

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors

0 references

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

0 references

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

0 references

ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy

0 references

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia

0 references

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

0 references

Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma

0 references

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma

0 references

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain

0 references

Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma

0 references

Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature

0 references

HER2 activating mutations are targets for colorectal cancer treatment

0 references

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

0 references

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

0 references

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

0 references

Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer

0 references

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

0 references

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

0 references

Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma

0 references

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

0 references

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

0 references

Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib

0 references

Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer

0 references

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

0 references

A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy

0 references

Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients

0 references

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

0 references

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

0 references

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

0 references

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

0 references

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

0 references

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

0 references

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

0 references

Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.

0 references

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

0 references

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells

0 references

OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer

0 references

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report

0 references

LRP1B deletion is associated with poor outcome for glioblastoma patients

0 references

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

0 references

MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.

0 references

The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma

0 references

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

0 references

Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma

0 references

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

0 references

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

0 references

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors

0 references

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer

0 references

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

0 references

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

0 references

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

0 references

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

0 references

Mutant HRAS as novel target for MEK and mTOR inhibitors

0 references

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib

0 references

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

0 references

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

0 references

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

0 references

HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report

0 references

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations

0 references

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

0 references

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

0 references

Increased expression of MyD88 and association with paclitaxel resistance in breast cancer

0 references

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

0 references

Elevated expression of RIT1 correlates with poor prognosis in endometrial cancer

0 references

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

0 references

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

0 references

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.

0 references

Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma

0 references

Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model

0 references

TP53 mutational status is predictive of pazopanib response in advanced sarcomas

0 references

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

0 references

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

0 references

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status

0 references

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer

0 references

FGFR1 is an adverse outcome indicator for luminal A breast cancers

0 references

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

0 references

Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis

0 references

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

0 references

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

0 references

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

0 references

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

0 references

Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With [...]

0 references

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer

0 references

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

0 references

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.

0 references

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations

0 references

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

0 references

Osimertinib: First Global Approval

0 references

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

0 references

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

0 references

Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer

0 references

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

0 references

TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun

0 references

TERT mutation in glioma: Frequency, prognosis and risk

0 references

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

0 references

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

0 references

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

0 references

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo

0 references

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.

0 references

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

0 references

Assessment of Minimal Residual Disease in Standard-Risk AML.

0 references

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

0 references

Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer

0 references

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer

0 references

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.

0 references

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

0 references

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

0 references

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

0 references

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

0 references

Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer

0 references

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer

0 references

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes

0 references

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

0 references

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

0 references

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

0 references

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

0 references

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

0 references

Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.

0 references

A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer

0 references

High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study

0 references

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine

0 references

Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model

0 references

Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade

0 references

PSMB8 and PBK as potential gastric cancer subtype-specific biomarkers associated with prognosis

0 references

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

0 references

Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up

0 references

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

0 references

Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma

0 references

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

0 references

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

0 references

Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.

0 references

Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer

0 references

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

0 references

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies

0 references

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

0 references

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

0 references

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation

0 references

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

0 references

KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer

0 references

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients

0 references

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

0 references

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults

0 references

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

0 references

The MKK7 p.Glu116Lys Rare Variant Serves as a Predictor for Lung Cancer Risk and Prognosis in Chinese

0 references

An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model

0 references

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

0 references

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy

0 references

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

0 references

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations

0 references

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

0 references

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

0 references

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

0 references

Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.

0 references

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

0 references

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

0 references

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

0 references

Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow

0 references

The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma

0 references

Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer

0 references

Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia

0 references

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

0 references

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

0 references

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer

0 references

Genomic Classification and Prognosis in Acute Myeloid Leukemia

0 references

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

0 references

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

0 references

Comprehensive mutation profiling of mucinous gastric carcinoma

0 references

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

0 references

Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis

0 references

Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection

0 references

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

0 references

Toward the molecular dissection of peritoneal pseudomyxoma.

0 references

Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia

0 references

The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.

0 references

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

0 references

Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway

0 references

p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma

0 references

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: ...

0 references

0 references

1 reference

https://www.wikidata.org/wiki/Wikidata:Property_proposal/CIViC_gene_ID

(Q27612411)

CIViC database

Statements

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)